| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating | 
|---|
																	
																	
																	Canaccord Genuity analyst Kyle Mikson maintains Exagen (NASDAQ:XGN) with a Buy and raises the price target from $11 to $15.
																	
																	BTIG analyst Mark Massaro maintains Exagen (NASDAQ:XGN) with a Buy and raises the price target from $11 to $13.
																	Keybanc analyst Paul Knight maintains Exagen (NASDAQ:XGN) with a Overweight and raises the price target from $12 to $15.
																	
																	B. Riley Securities analyst Anderson Schock initiates coverage on Exagen (NASDAQ:XGN) with a Buy rating and announces Price ...
																	Canaccord Genuity analyst Kyle Mikson maintains Exagen (NASDAQ:XGN) with a Buy and raises the price target from $8 to $11.